| 1.27 0 (0%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.54 | 1-year : | 1.59 |
| Resists | First : | 1.32 | Second : | 1.36 |
| Pivot price | 1.27 | |||
| Supports | First : | 1.25 | Second : | 1.03 |
| MAs | MA(5) : | 1.27 | MA(20) : | 1.27  |
| MA(100) : | 1.24  |
MA(250) : | 5.52 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.9 |
D(3) : | 36.1 |
| RSI | RSI(14): 47.9 | |||
| 52-week | High : | 22.5 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IGMS ] has closed above bottom band by 38.0%. Bollinger Bands are 75.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.27 - 1.28 | 1.28 - 1.28 |
| Low: | 1.25 - 1.26 | 1.26 - 1.27 |
| Close: | 1.26 - 1.27 | 1.27 - 1.28 |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Thu, 14 Aug 2025
IGM Biosciences Merges with Concentra Biosciences - TipRanks
Thu, 31 Jul 2025
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates - Nasdaq
Tue, 01 Jul 2025
Hedge fund plots takeout of IGM Biosciences, its third Bay Area biotech zombie deal in three months - The Business Journals
Tue, 01 Jul 2025
IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders - The AI Journal
Tue, 01 Jul 2025
Concentra to acquire IGM Biosciences for $1.247 per share plus CVR - Investing.com
Tue, 01 Jul 2025
IGM Biosciences Enters into Agreement to Be Acquired by - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 2.435e+007 (%) |
| Held by Institutions | 35.3 (%) |
| Shares Short | 394 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.763e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -36.9 % |
| Operating Margin | 90.7 % |
| Return on Assets (ttm) | 2.8 % |
| Return on Equity (ttm) | -47.9 % |
| Qtrly Rev. Growth | 11 % |
| Gross Profit (p.s.) | 598.64 |
| Sales Per Share | 2.45847e+008 |
| EBITDA (p.s.) | -9.30509e+006 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -157 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.44 |
| Dividend | 0 |
| Forward Dividend | 452130 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|